Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (21-30 of 224) with videos related to

Pageof 23
Sort By:
Cancer Journal (Sudbury, Mass.)|November 26, 2019
BCL-2 Inhibitors, Present and FutureChristine E Ryan, Matthew S Davids
Blood|December 25, 2025
Acalabrutinib to assail CLL in the frailChristine E Ryan, Matthew S Davids
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2015
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of ApoptosisChristopher J Gibson, Matthew S Davids
Hematology/Oncology Clinics of North America|July 24, 2025
Triplet Therapies in Chronic Lymphocytic LeukemiaJacob D Soumerai, Matthew S Davids
Hematology/Oncology Clinics of North America|April 9, 2013
Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemiaMatthew S Davids, Jennifer R Brown
Leukemia & Lymphoma|May 24, 2012
Targeting the B cell receptor pathway in chronic lymphocytic leukemiaMatthew S Davids, Jennifer R Brown
Blood|October 13, 2018
A new triple threat to CLLBenjamin L Lampson, Matthew S Davids
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 4, 2023
Practical Management of Richter Transformation in 2023 and BeyondChristine E Ryan, Matthew S Davids
Future Oncology (London, England)|June 20, 2014
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseMatthew S Davids, Jennifer R Brown
Current Hematologic Malignancy Reports|February 16, 2015
The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemiaMatthew S Davids, Edwin P Alyea
Pageof 23

Showing results (21-30 of 224) with videos related to

Sort By:
Pageof 23
Cancer Journal (Sudbury, Mass.)|November 26, 2019
BCL-2 Inhibitors, Present and FutureChristine E Ryan, Matthew S Davids
Blood|December 25, 2025
Acalabrutinib to assail CLL in the frailChristine E Ryan, Matthew S Davids
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2015
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of ApoptosisChristopher J Gibson, Matthew S Davids
Hematology/Oncology Clinics of North America|July 24, 2025
Triplet Therapies in Chronic Lymphocytic LeukemiaJacob D Soumerai, Matthew S Davids
Hematology/Oncology Clinics of North America|April 9, 2013
Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemiaMatthew S Davids, Jennifer R Brown
Leukemia & Lymphoma|May 24, 2012
Targeting the B cell receptor pathway in chronic lymphocytic leukemiaMatthew S Davids, Jennifer R Brown
Blood|October 13, 2018
A new triple threat to CLLBenjamin L Lampson, Matthew S Davids
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 4, 2023
Practical Management of Richter Transformation in 2023 and BeyondChristine E Ryan, Matthew S Davids
Future Oncology (London, England)|June 20, 2014
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseMatthew S Davids, Jennifer R Brown
Current Hematologic Malignancy Reports|February 16, 2015
The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemiaMatthew S Davids, Edwin P Alyea
Pageof 23